Business
Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results
Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0%Fourth quarter GAAP earnings of $0.21 per diluted share compared to
About this update from Bioventus Inc.
[{"type":"text","content":"Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0%Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year periodNon-GAAP earnings* of $0.24 per diluted shareFourth quarter cash from operations of $38.0 million increased 97%2026 financial guidance reflects continued above-market revenue growth, higher earnings and robust cash generation DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2025, and provided its financial guidance for full-year 2026. \"Our team delivered strong fourth quarter performance, concluding an important year in which we strengthened our portfolio, drove above-market growth, improved margins, and strengthened our balance sheet,” said Rob Claypoole, Bioventus President and Chief Executive Officer. “These results reflect continued demand for our market-leading therapies, and disciplined execution across our commercial and operational initiatives. We are entering 2026 from a position of strength and plan to invest to further accelerate our growth while expanding profitability and generating meaningful cash flow. We believe this is a powerful combination that positions Bioventus to deliver increased shareholder value.” Fourth Quarter 2025 Financial Results For the fourth quarter, worldwide revenue totaled $157.9 million, advancing 10.0% on an organic* basis driven by double-digit organic* growth across Pain Treatments and Surgical Solutions. Reported revenue increased 2.8% from $153.6 million in the prior-year period due to the impact of the prior-year divestiture of the Advanced Rehabilitation Business. Net income attributable to Bioventus Inc. was $14.8 million, compared to net loss attributable to Bioventus Inc. of $0.4 million in the prior-year period. Adjusted EBITDA* of $36.7 million advanced 30% from $28.3 million in the prior-year period as a result of higher organic* revenue growth, increased gross margin and disciplined spending. GAAP earnings of $0.21 per diluted share of Class A common stock improved from no income per share in the prior-year period. Adjusted Earnings Per Share (Adjusted EPS)* of Class A common stock of $0.24...